The Indian Pharmacopoeia Commission (IPC) issued a drug safety alert in December 2023 advising healthcare professionals and patients to monitor adverse reactions to ‘Meftal’, which has _______ properties

Correct option is B

The correct answer is (B) antipyretic.

In December 2023, the Indian Pharmacopoeia Commission (IPC) issued a drug safety alert advising healthcare professionals and patients to monitor adverse reactions associated with Meftal, a medication containing mefenamic acid. Meftal is widely used for its antipyretic (fever-reducing) and analgesic (pain-relieving) properties, commonly prescribed for menstrual cramps, rheumatoid arthritis, osteoarthritis, mild to moderate pain, inflammation, and dental pain.

Information Booster

• Mefenamic Acid: The active ingredient in Meftal, mefenamic acid, is a non-steroidal anti-inflammatory drug (NSAID) known for its effectiveness in reducing pain and fever.
• Drug Safety Alert: The IPC's alert was based on a preliminary analysis of adverse drug reactions, highlighting the importance of monitoring for potential side effects when using Meftal.
• Medical Applications: Meftal is frequently prescribed for fever management, pain relief, and inflammatory conditions, making it a versatile NSAID in clinical practice.

Additional Information

• (A) Antipruritic: Used to relieve itching and skin irritation, commonly found in anti-allergy medications.
• (C) Antacid: Helps neutralize stomach acid, often used for acid reflux and gastritis treatment.
• (D) Antihistamine: Used to treat allergic reactions by blocking histamine effects, commonly prescribed for allergies, colds, and sinus issues.